Gilead registers Phase 2/3 HIV combo trial and Phase 1 oncology study for GS-1206
Two new Gilead trials began recruiting in July 2026: a Phase 2/3 HIV-1 study pairing GS-3242 with lenacapavir against Biktarvy, and a Phase 1 solid tumor study of GS-1206.
Gilead Sciences has two newly recruiting studies this week, one in HIV-1 treatment and one in oncology.
- Gilead's Phase 2/3 study (NCT07708727) is evaluating an injectable regimen of GS-3242 plus lenacapavir versus Biktarvy in people new to HIV-1 treatment.1 The trial is recruiting an estimated 700 participants,1 and the Phase 3 portion will assess long-term effectiveness of GS-3242 and lenacapavir versus B/F/TAF at Week 52.1
- Gilead's Phase 1 study (NCT07703878) is testing the safety, tolerability, and antitumor activity of GS-1206 in adult participants with solid tumors,2 with an estimated enrollment of 302 participants.2 The study lists three primary outcomes: the percentage of participants experiencing any dose-limiting toxicities,2 the percentage of participants experiencing treatment-emergent adverse events and serious adverse events based on NCI CTCAE v6.0,2 and the percentage of participants experiencing clinical laboratory abnormalities based on the same criteria.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.